Literature DB >> 6238552

The pharmacokinetics of sufentanil in surgical patients.

J G Bovill, P S Sebel, C L Blackburn, V Oei-Lim, J J Heykants.   

Abstract

The pharmacokinetics of sufentanil, a new thienyl analogue of fentanyl, were studied in 10 surgical patients. Sufentanil, 5 micrograms/kg, was given intravenously as a bolus injection and plasma concentrations measured at intervals up to 8 h. Plasma sufentanil concentrations decreased rapidly after injection--98% of the administered dose having left the plasma within 30 min. In 9 of the 10 patients, a tri-exponential equation optimally described the sufentanil concentration decay curve, with average (+/-SEM) half-lives for the rapid (pi) and slow (alpha) distribution phases of 1.4 +/- 0.3 min and 17.7 +/- 2.6 min, respectively. The average terminal elimination (beta) half-life was 164 +/- 22 min. The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min). In one patient, a bi-exponential equation was sufficient to describe the concentration-time data, yielding a distribution half-life of 4.7 min and an elimination half-life of 117 min.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238552     DOI: 10.1097/00000542-198411000-00004

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  36 in total

1.  Pharmacokinetics of sufentanil.

Authors:  T H Kramer; R C Cork; A J Gandolfi
Journal:  Can J Anaesth       Date:  1989-07       Impact factor: 5.063

2.  Anaesthesia for a patient with central alveolar hypoventilation syndrome (Ondine's Curse).

Authors:  S Wiesel; G S Fox
Journal:  Can J Anaesth       Date:  1990-01       Impact factor: 5.063

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 4.  Sufentanil. A review of its pharmacological properties and therapeutic use.

Authors:  J P Monk; R Beresford; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

5.  Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery.

Authors:  M Borenstein; R Shupak; R Barnette; G Cooney; W Johnson; T B Tzeng
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

6.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

7.  Sufentanil disposition during cardiopulmonary bypass.

Authors:  P Flezzani; M J Alvis; J R Jacobs; M M Schilling; S Bai; J G Reves
Journal:  Can J Anaesth       Date:  1987-11       Impact factor: 5.063

Review 8.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 9.  [Opioids during anesthesia in liver and renal failure].

Authors:  C Höhne; B Donaubauer; U Kaisers
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

10.  Comparative absorption and distribution pharmacokinetics of intravenous and epidural sufentanil for major abdominal surgery.

Authors:  R H Taverne; T I Ionescu; S T Nuyten
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.